LOS ANGELES, CA / ACCESSWIRE / August 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioXcel Therapeutics, Inc. ("BioXcel" or "the Company") (NASDAQ: BTAI) for violations of ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between December 15, 2021 and June 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 5, 2023.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. BioXcel failed to maintain appropriate internal controls over data integrity and protocol adherence. The Company's principal investigator failed to utilize the Institutional Review Board's approved informed consent form. The Company's principal investigator failed to maintain appropriate patient histories. The Company's principal investigator faked email correspondence with a pharmacovigilance safety vendor which was then provided to the FDA. These failures would impact the Company's chances of receiving approval for its drug candidate, BXCL501. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about BioXcel, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
SOURCE: The Schall Law Firm
View source version on accesswire.com:
https://www.accesswire.com/772523/shareholder-action-alert-the-schall-law-firm-encourages-investors-in-bioxcel-therapeutics-inc-with-losses-of-100000-to-contact-the-firm
